Apellis Pharmaceuticals announced its participation in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The company, a global biopharmaceutical leader in complement science, has two C3-targeting medicines approved for four serious diseases, including the first therapy for geographic atrophy and treatments for rare kidney diseases.

S&P Dow Jones Indices announced index changes effective January 30 and February 2, 2026. TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT will be promoted to the S&P MidCap 400, while Amneal Pharmaceuticals, Apellis Pharmaceuticals, and LegalZoom.com will join the S&P SmallCap 600. These changes follow several pending M&A transactions and corporate actions.

Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta slid 4% on soft guidance, while Moderna rallied 14% on bullish forecasts. Intel and AMD gained on analyst upgrades. Energy stocks outperformed as crude rose 2.7% to $61/barrel.

Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached over 5% market penetration in its target indications within five months of launch. The company maintains approximately $466 million in cash and expects to reach profitability through product revenues.

The geographic atrophy market is expected to grow significantly due to rising global prevalence, aging populations, and emerging therapies targeting this advanced form of age-related macular degeneration.

Apellis Pharmaceuticals reported $459 million in Q3 2025 revenues, with $178 million from U.S. net product sales. The company highlighted new one-year data for EMPAVELI® demonstrating sustained efficacy in treating kidney diseases.

The complement 3 glomerulopathy market is projected to grow at a 37.2% CAGR from 2025-2034, driven by increasing disease awareness, advances in complement pathway research, and emerging targeted therapies targeting novel complement mechanisms.

Apellis Pharmaceuticals presented one-year clinical data for EMPAVELI, demonstrating sustained proteinuria reduction and kidney function stabilization in patients with rare kidney diseases C3G and IC-MPGN, with indirect comparisons suggesting superiority over competitor iptacopan.

Apellis Pharmaceuticals announced participation in upcoming healthcare investor conferences and highlighted recent FDA approval of EMPAVELI for treating C3G and primary IC-MPGN in patients 12 and older.

The FDA approved EMPAVELI® (pegcetacoplan) as the first treatment for rare kidney diseases C3G and primary IC-MPGN in patients 12 and older, demonstrating a 68% reduction in proteinuria and stabilization of kidney function in clinical trials.

The age-related macular degeneration (AMD) market is expected to grow due to the launch of new therapies and increased healthcare spending. Dry AMD and wet AMD are the two main types, with new treatments in development for both.

Apellis Pharmaceuticals reported a Q1 revenue decline and wider net loss, missing analyst expectations. However, the company continues to develop its drugs Syfovre and Empaveli for new indications, with an FDA decision on Empaveli expected in July.